Portage Biotech, Inc. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Mar'19
No of Months
12
12
12
12
12
12
Profit Before Tax
-85.00
-122.00
-14.00
-14.00
-6.00
-3.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
-14.00
-12.00
-6.00
-4.00
-3.00
0.00
Cash Flow from Investing Activities
2.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Financing Activities
5.00
0.00
27.00
4.00
0.00
0.00
Net Cash Inflow / Outflow
-5.00
-12.00
20.00
0.00
-3.00
-1.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in USD Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Portage Biotech, Inc.
Figures in Million
consolidated Cash Flow Results
Change(USD)
Change(%)
Profit Before Tax
-85.697
-64.767
-21.00
-32.32%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
0.982
4.204
-4.00
-76.64%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
-14.297
-47.956
33.00
70.19%
Cash Flow from Investing Activities
2.812
54.946
-52.00
-94.88%
Cash Flow from Financing Activities
5.968
8.874
-3.00
-32.75%
Net Cash Inflow / Outflow
-5.517
15.864
-20.00
-134.78%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Mar'24
YoY Growth in year ended Mar 2024 is -18.42% vs -78.49% in Mar 2023
Mar'24
Mar'23
Change(%)
Cash Flow from Operating Activities
-14.30
-12.07
-18.42%






